Literature DB >> 26876193

Myasthenia gravis due to hydroxychloroquine.

O Varan1, H Kucuk, A Tufan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26876193     DOI： 10.4081/reumatismo.2015.849

Source DB:  PubMed          Journal:  Reumatismo        ISSN： 0048-7449


× No keyword cloud information.
  8 in total

1.  Hydroxychloroquine and Myasthenia Gravis-Can One Take This Risk?

Authors:  Arunmozhimaran Elavarasi; Vinay Goyal
Journal:  Ann Indian Acad Neurol       Date:  2020-06-10       Impact factor: 1.383

Review 2.  Association of early-onset myasthenia gravis and primary Sjögren's syndrome: a case-based narrative review.

Authors:  Marc Hartert; Balint Melcher; Martin Huertgen
Journal:  Clin Rheumatol       Date:  2022-08-01       Impact factor: 3.650

3.  Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort.

Authors:  Antonino Lupica; Vincenzo Di Stefano; Salvatore Iacono; Antonia Pignolo; Martina Quartana; Andrea Gagliardo; Brigida Fierro; Filippo Brighina
Journal:  Neurol Int       Date:  2022-04-27

4.  Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.

Authors:  G Solé; E Salort-Campana; Y Pereon; T Stojkovic; K Wahbi; P Cintas; D Adams; P Laforet; V Tiffreau; I Desguerre; L I Pisella; A Molon; S Attarian
Journal:  Rev Neurol (Paris)       Date:  2020-04-20       Impact factor: 2.607

5.  Perspectives of Neuro-COVID: Myasthenia.

Authors:  Josef Finsterer; Fulvio A Scorza
Journal:  Front Neurol       Date:  2021-02-26       Impact factor: 4.003

6.  MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine.

Authors:  Shalini Bhaskar; Mohammed Fauzi Bin Abdul Rani
Journal:  Case Rep Med       Date:  2022-07-15

Review 7.  Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic.

Authors:  Gianluca Costamagna; Elena Abati; Nereo Bresolin; Giacomo Pietro Comi; Stefania Corti
Journal:  J Neurol       Date:  2020-08-17       Impact factor: 4.849

Review 8.  COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs

Authors:  Abdurrahman Tufan; Aslihan Avanoğlu Güler; Marco Matucci-Cerinic
Journal:  Turk J Med Sci       Date:  2020-04-21       Impact factor: 0.973
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.